Khartis Therapeutics
Develops oral small molecule therapies for immunological and chronic diseases
$50MSeries B
Role not disclosedFL
Forge Life Science Partners
Activity from announced rounds
Activity in this selectionOct 16, 2026 · Jul 19, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $125M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionInfinimmune
Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease
$75MSeries A
Role not disclosed